Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients

Table 3 Treatment outcomes between Group A and Group B

	Group A (n = 22 eyes)	Group B (n = 8 eyes)	P-value
Keratopathy	19	2	0.003^a
Recurrence of the CNS lymphoma	6	3	0.666^a
Follow-up time (month)	21	27	0.303^b
Initial VA (LogMAR)	0.64	0.68	0.901^b
Final VA (LogMAR)	0.32	0.18	0.517^b

Group A = treated with induction-consolidation-maintenance regimen, Group B = treated with induction-maintenance regimen. ^a Fisher’s exact test, ^b t-test. VA visual acuity, CNS central nervous system

ISSN: 1471-2415